Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, November 8, 2022
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
[ Tue, Nov 08th 2022
] - WOPRAI
Mon, November 7, 2022
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
[ Mon, Nov 07th 2022
] - WOPRAI
Mark Massaro Maintained (CDNA) at Strong Buy with Decreased Target to $28 on, Nov 7th, 2022
Mark Massaro of BTIG, Maintained "CareDx, Inc" (CDNA) at Strong Buy with Decreased Target from $37 to $28 on, Nov 7th, 2022.
Mark has made no other calls on CDNA in the last 4 months.
There are 2 other peers that have a rating on CDNA. Out of the 2 peers that are also analyzing CDNA, 0 agree with Mark's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Mark
- Matthew Sykes of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $40 on, Friday, November 4th, 2022
- Andrew Cooper of "Raymond James" Maintained at Strong Buy with Decreased Target to $35 on, Wednesday, August 10th, 2022
